Opposite/JJ
effects/NNS
of/IN
the/DT
acute/JJ
promyelocytic/JJ
leukemia/NN
PML-retinoic/JJ
acid/NN
receptor/NN
alpha/NN
(/(
RAR/NN
alpha/NN
)/)
and/CC
PLZF-RAR/NN
alpha/NN
fusion/NN
proteins/NNS
on/IN
retinoic/JJ
acid/NN
signalling/NN
./.

Fusion/NN
proteins/NNS
involving/VBG
the/DT
retinoic/JJ
acid/NN
receptor/NN
alpha/NN
(/(
RAR/NN
alpha/NN
)/)
and/CC
the/DT
PML/NN
or/CC
PLZF/NN
nuclear/JJ
protein/NN
are/VBP
the/DT
genetic/JJ
markers/NNS
of/IN
acute/JJ
promyelocytic/JJ
leukemias/NNS
(/(
APLs/NNS
)/)
./.
=====
APLs/NNS
with/IN
the/DT
PML-RAR/NN
alpha/NN
or/CC
the/DT
PLZF-RAR/NN
alpha/NN
fusion/NN
protein/NN
are/VBP
phenotypically/RB
indistinguishable/JJ
except/IN
that/IN
they/PRP
differ/VBP
in/IN
their/PRP$
sensitivity/NN
to/TO
retinoic/JJ
acid/NN
(/(
RA/NN
)/)
-induced/JJ
differentiation/NN
:/:
PML-RAR/NN
alpha/NN
blasts/NNS
are/VBP
sensitive/JJ
to/TO
RA/NN
and/CC
patients/NNS
enter/VBP
disease/NN
remission/NN
after/IN
RA/NN
treatment/NN
,/,
while/IN
patients/NNS
with/IN
PLZF-RAR/NN
alpha/NN
do/VBP
not/RB
./.
=====
We/PRP
here/RB
report/VBP
that/IN
(/(
i/LS
)/)
like/IN
PML-RAR/NN
alpha/NN
expression/NN
,/,
PLZF-RAR/NN
alpha/NN
expression/NN
blocks/VBZ
terminal/JJ
differentiation/NN
of/IN
hematopoietic/JJ
precursor/NN
cell/NN
lines/NNS
(/(
U937/NN
and/CC
HL-60/NN
)/)
in/IN
response/NN
to/TO
different/JJ
stimuli/NNS
(/(
vitamin/NN
D3/NN
,/,
transforming/VBG
growth/NN
factor/NN
beta1/NN
,/,
and/CC
dimethyl/NN
sulfoxide/NN
)/)
;/:
(/(
ii/LS
)/)
PML-RAR/NN
alpha/NN
,/,
but/CC
not/RB
PLZF-RAR/NN
alpha/NN
,/,
increases/VBZ
RA/NN
sensitivity/NN
of/IN
hematopoietic/JJ
precursor/NN
cells/NNS
and/CC
restores/VBZ
RA/NN
sensitivity/NN
of/IN
RA-resistant/JJ
hematopoietic/JJ
cells/NNS
;/:
(/(
iii/LS
)/)
PML-RAR/NN
alpha/NN
and/CC
PLZF-RAR/NN
alpha/NN
have/VBP
similar/JJ
RA/NN
binding/NN
affinities/NNS
;/:
and/CC
(/(
iv/LS
)/)
PML-RAR/NN
alpha/NN
enhances/VBZ
the/DT
RA/NN
response/NN
of/IN
RA/NN
target/NN
genes/NNS
(/(
those/DT
for/IN
RAR/NN
beta/NN
,/,
RAR/NN
gamma/NN
,/,
and/CC
transglutaminase/NN
type/NN
II/CD
[/(
TGase/NN
]/)
)/)
in/FW
vivo/FW
,/,
while/IN
PLZF-RAR/NN
alpha/NN
expression/NN
has/VBZ
either/CC
no/DT
effect/NN
(/(
RAR/NN
beta/NN
)/)
or/CC
an/DT
inhibitory/JJ
activity/NN
(/(
RAR/NN
gamma/NN
and/CC
type/NN
II/CD
TGase/NN
)/)
./.
=====
These/DT
data/NNS
demonstrate/VBP
that/IN
PML-RAR/NN
alpha/NN
and/CC
PLZF-RAR/NN
alpha/NN
have/VBP
similar/JJ
(/(
inhibitory/JJ
)/)
effects/NNS
on/IN
RA-independent/JJ
differentiation/NN
and/CC
opposite/JJ
(/(
stimulatory/JJ
or/CC
inhibitory/JJ
)/)
effects/NNS
on/IN
RA-dependent/JJ
differentiation/NN
and/CC
that/IN
they/PRP
behave/VBP
in/FW
vivo/FW
as/IN
RA-dependent/JJ
enhancers/NNS
or/CC
inhibitors/NNS
of/IN
RA-responsive/JJ
genes/NNS
,/,
respectively/RB
./.
=====
Their/PRP$
different/JJ
activities/NNS
on/IN
the/DT
RA/NN
signalling/NN
pathway/NN
might/MD
underlie/VB
the/DT
different/JJ
responses/NNS
of/IN
PML-RAR/NN
alpha/NN
and/CC
PLZF-RAR/NN
alpha/NN
APLs/NNS
to/TO
RA/NN
treatment/NN
./.
=====
The/DT
PLZF-RAR/NN
alpha/NN
fusion/NN
protein/NN
contains/VBZ
an/DT
approximately/RB
120-amino-acid/JJ
N-terminal/JJ
motif/NN
(/(
called/VBN
the/DT
POZ/NN
domain/NN
)/)
,/,
which/WDT
is/VBZ
also/RB
found/VBN
in/IN
a/DT
variety/NN
of/IN
zinc/NN
finger/NN
proteins/NNS
and/CC
a/DT
group/NN
of/IN
poxvirus/NN
proteins/NNS
and/CC
which/WDT
mediates/VBZ
protein-protein/JJ
interactions/NNS
./.
=====
Deletion/NN
of/IN
the/DT
PLZF/NN
POZ/NN
domain/NN
partially/RB
abrogated/VBD
the/DT
inhibitory/JJ
effect/NN
of/IN
PLZF-RAR/NN
alpha/NN
on/IN
RA-induced/JJ
differentiation/NN
and/CC
on/IN
RA-mediated/JJ
type/NN
II/CD
TGase/NN
up-regulation/NN
,/,
suggesting/VBG
that/IN
POZ-mediated/JJ
protein/NN
interactions/NNS
might/MD
be/VB
responsible/JJ
for/IN
the/DT
inhibitory/JJ
transcriptional/JJ
activities/NNS
of/IN
PLZF-RAR/NN
alpha/NN
./.